Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention

NCT07156591 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 460

Last updated 2025-09-05

No results posted yet for this study

Summary

A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted semaglutide therapy

Conditions

  • Gastric Retention

Interventions

PROCEDURE

Esophagogastroduodenoscopy

Assess the gastric retention during esophagogastroduodenoscopy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Danian Ji, M.D. · Huadong Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2028-09-15
Completion
2028-09-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07156591 on ClinicalTrials.gov